LONDON — Gene therapy specialist Oxford Biomedica plc, of Oxford, has signed two exclusive research collaborations with U.S. partners.

The first, with the National Institutes of Health (NIH) Clinical Gene Therapy Branch at the National Human Genome Research Institute, in Bethesda, Md., will bring together Oxford Biomedica's lentivirus gene vector technology with the NIH's dual virus vector system. The systems developed as a result are expected to be applicable to a wide variety of diseases.

The second collaboration, with the University of North Carolina at Chapel Hill, will further develop the company's equine infectious anemia virus lentiviral technology. —Nuala Moran